Tris-Hydroxymethyl Aminomethane in Critically Ill Adults: A Systematic Review.
Misty A Radosevich, Patrick M Wieruszewski, Erica D Wittwer
https://pubmed.ncbi.nlm.nih.gov/37075790/Actively Recruiting
Led by Mayo Clinic · Updated on 2026-09-21
250
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are comparing two common treatments, tris-hydroxymethyl aminomethane THAM and sodium bicarbonate, to see if they work equally well for metabolic acidosis in patients after cardiac surgery using cardiopulmonary bypass. This study focuses on adults who develop significant metabolic acidosis, measured by a base excess less than -5, after their surgery. The trial is a Phase 4, randomized study designed to evaluate treatment effectiveness in a real-world setting. Participants are randomly assigned to receive either THAM or sodium bicarbonate when their metabolic acidosis meets the criteria. Patients in the THAM group receive 500 mL of THAM, while those in the sodium bicarbonate group receive 100 mEq of sodium bicarbonate. Both treatments are given in the intensive care unit following cardiothoracic surgery. The study tracks changes shortly after treatment to compare the two medications. During the trial, participants are monitored closely with measurements taken at baseline and two hours after buffer administration, including pH, sodium, potassium, lactate levels, carbon dioxide pressure, cardiac index, blood pressure, vasopressor and inotrope doses. Additional outcomes such as duration of mechanical ventilation, incidence of acute kidney injury, renal replacement therapy, and lengths of ICU and hospital stays are assessed within seven days. The study runs from September 2026 to June 2028, with primary results expected by December 2027.
CONDITIONS
A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients
N
Nicole M. Lenort, RRT, LRT
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mayo Clinic
Lead Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | THAM | Sodium bicarbonate |
|---|---|---|
| What it is | An investigational buffer agent (THAM) given to patients after cardiac surgery who develop metabolic acidosis (base excess <-5) | An active comparator buffer agent (sodium bicarbonate) given to patients after cardiac surgery with metabolic acidosis (base excess <-5) |
| Role in trial | Randomized experimental treatment arm | Randomized active comparator arm |
| Primary use in trial | To correct postoperative metabolic acidosis after cardiothoracic surgery with bypass | To correct postoperative metabolic acidosis after cardiothoracic surgery with bypass |
| How it is given | THAM administered intravenously to patients with base excess <-5 in ICU after cardiac surgery | Sodium bicarbonate administered intravenously to patients with base excess <-5 in ICU after cardiac surgery |
| Evidence status | Preclinical and retrospective data show THAM may raise pH and mean arterial pressure without causing sodium or CO₂ excess | Sodium bicarbonate is known to raise blood bicarbonate and pH but can increase CO₂ load and sodium levels |
| Important risks | Potential risks include respiratory depression, hypoglycemia, and need for renal excretion monitoring | Risks include CO₂ generation, sodium overload, fluid expansion, and paradoxical intracellular acidosis |
| Important limitations | Evidence is currently based on retrospective comparison and no randomized trial results are available yet | Standard use is widespread but may exacerbate CO₂ load and electrolyte imbalance in ventilated patients |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Short-term following surgery
Participants receive either tris-hydroxymethyl aminomethane (THAM) or sodium bicarbonate based on random assignment when metabolic acidosis is detected after cardiac surgery.
Assessments at baseline and 2 hours after treatment
Duration - 7 days
Participants are monitored for outcomes such as ventilation duration, kidney function, and length of hospital stay over seven days after treatment.
Regular clinical assessments during hospital stay
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Misty A Radosevich, Patrick M Wieruszewski, Erica D Wittwer
https://pubmed.ncbi.nlm.nih.gov/37075790/Mayo Clinic
Lead Sponsor